ArticleFrontiers in immunology2025
Identification and validation of ubiquitination-associated genes of senile osteoporosis based on bioinformatics analysis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Senile osteoporosis (SOP) is linked to the ubiquitination process, with dysregulation of ubiquitin-mediated protein turnover disrupting bone remodeling and resulting in decreased bone mineral density (BMD). This study aimed to identify biomarkers related to ubiquitination in SOP and explore their molecular regulatory mechanisms. Methods: Transcriptomic data of SOP samples (categorized by high and low BMD) were obtained from public databases. Differential expression analysis, protein-protein interaction networks, and the CytoHubba plugin (using Maximum Neighborhood Component and degree algorithms) were utilized, alongside the Least Absolute Shrinkage and Selection Operator, to identify ubiquitination-related genes (URGs) as potential SOP biomarkers. The diagnostic potential of these biomarkers was assessed through a Support Vector Machine model and a nomogram. Their molecular mechanisms were further investigated using enrichment analysis, immune infiltration analysis, and the construction of regulatory networks. Expression levels of the biomarkers were validated in a SOP rat model, with enzyme-linked immunosorbent assay applied to detect relevant indices. Results: RPS27A and UBE2E1 were significantly underexpressed in low BMD samples and demonstrated a strong ability to differentiate between patients with varying BMDs, making them potential diagnostic biomarkers for SOP. A positive correlation was observed between RPS27A and UBE2E1 (cor = 0.35, Conclusion: This study successfully identified RPS27A and UBE2E1 as key biomarkers for SOP, demonstrating their diagnostic potential and involvement in important biological pathways and immune responses, thus offering new prospects for therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.